Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Pyruvate Imaging of Glioma
NCT03830151Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [1-13C]pyruvate in glioma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Successful collection of hyperpolarized pyruvate magnetic resonance (MR) (HMR) imaging data at 1 year. Started May 2019; status: recruiting.
02
Drugs
[1-13C]pyruvate
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03830151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830151.